Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)

  Print      Mail a friend

Friday 20 December, 2019

Sensyne Health PLC

Notice of Results

RNS Number : 6253X
Sensyne Health PLC
20 December 2019
 

 

 

 

Notice of Interim Results

 

Oxford, UK; 20 December 2019: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, will announce its Interim Results for the 6 months ended 31 October 2019 on Tuesday 21 January 2020.

 

Lord (Paul) Drayson, Chief Executive Officer, and Lorimer Headley, Chief Financial Officer, will host a briefing for analysts at 12.00pm GMT on the day of the results at 1 Moorgate Place, London, EC2R 6EA.

 

A live webcast of the meeting, with the presentation slides, will be available via the Company's website.

 

 

-ENDS-

 

 

For more information please contact:

 

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer

 

Lorimer Headley, Chief Financial Officer

 

 

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

Dr Christopher Golden

 

James Steel

 

Oliver Jackson

 

 

 

 

Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma

 

Euan Brown

 

 

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott

 

Sukaina Virji

 

Melissa Gardiner

 

 

 

 

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information, please visit: www.sensynehealth.com 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORVBLBLKLFXFBL

a d v e r t i s e m e n t